Lorlatinib Induced Non-cardiogenic Pulmonary Edema: A Case Report

被引：0
作者：
Matsuoka, Suzuka [1 ]
Watanabe, Hiromi [1 ]
Inoue, Tomoyoshi [1 ]
Takigawa, Yuki [1 ]
Kudo, Kenichiro [1 ]
Sato, Akiko [1 ]
Sato, Ken [1 ]
Fujiwara, Keiichi [1 ]
Shibayama, Takuo [1 ]
机构：
[1] NHO Okayama Med Ctr, Dept Resp Med, Okayama, Japan
来源：
INTERNAL MEDICINE | 2025年
关键词：
lorlatinib; ALK-positive lung adenocarcinoma; non-cardiogenic pulmonary edema; EGFR;
D O I：
10.2169/internalmedicine.5156-24
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A 71-year-old woman was diagnosed with anaplastic lymphoma kinase (ALK)-positive metastatic lung adenocarcinoma staged as cT1cN3M1c (8th edition). Treatment with lorlatinib (100 mg) was initiated on a daily basis. Three weeks after the first dose, the patient was hospitalized because of lorlatinib-induced noncardiogenic pulmonary edema. The patient's condition improved with diuretic therapy, and lorlatinib was rechallenged at a reduced dose. Follow-up computed tomography revealed a partial response. This is a rare case of non-cardiogenic pulmonary edema as an adverse effect of lorlatinib.
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Lorlatinib overcomes alectinib-induced hemolytic anemia in an ALK fusion positive non-small-cell lung cancer patient with severe tumor-associated liver failure: A case report
    Kunimasa, Kei
    Miyazaki, Akito
    Tamiya, Motohiro
    Inoue, Takako
    Kawamura, Takahisa
    Tanaka, Tsunehiro
    Futamura, Shun
    Komuta, Kiyohide
    Nagata, Shigenori
    Honma, Keiichiro
    Ohkawa, Kazuyoshi
    Nishino, Kazumi
    THORACIC CANCER, 2024, 15 (36) : 2570 - 2574
  • [42] Long-Term Response of Lorlatinib to Leptomeningeal Metastasis in Patients with Anaplastic Lymphoma Kinase Fusion Positive Non-Small Lung Cancer: A Case Report
    Fujiwara, Yutaka
    Masago, Katsuhiro
    Matsuzawa, Reiko
    Yamaguchi, Teppei
    Watanabe, Naohiro
    Shimizu, Junichi
    Sasaki, Eiichi
    Horio, Yoshitsugu
    CASE REPORTS IN ONCOLOGY, 2024, 17 (01): : 942 - 949
  • [43] Second-trimester medical abortion after exposure to lorlatinib during early pregnancy, a case report
    Mawet, Marie
    Basse, Clemence
    Barrois, Mathilde
    Gligorov, Joseph
    Cadranel, Jacques
    Chabbert-Buffet, Nathalie
    Selleret, Lise
    JOURNAL OF GYNECOLOGY OBSTETRICS AND HUMAN REPRODUCTION, 2023, 52 (10)
  • [44] Pathological complete response to neoadjuvant lorlatinib in a patient with unresectable ALK-Positive locally advanced non-small cell lung cancer: A case report
    Chen, Ruiqi
    Zhao, Lilan
    Zhang, Juan
    Guo, Lingwen
    Chen, Zhizhong
    Pan, Xiaojie
    Chen, Wenshu
    HELIYON, 2023, 9 (11)
  • [45] Enteral lorlatinib after immune hyperprogression as a treatment option for anaplastic lymphoma kinase-positive non-small cell lung cancer: A case report
    Wang, Huan
    Wu, Zhenyan
    Shi, Guangqing
    Zhou, Jing
    Xiao, Zhenliang
    ONCOLOGY LETTERS, 2023, 26 (06)
  • [46] Successful treatment with lorlatinib in a patient with meningeal carcinomatosis of ALK-positive non-small cell lung cancer resistant to alectinib and brigatinib A case report
    Nakashima, Koki
    Demura, Yoshiki
    Kurokawa, Kosuke
    Takeda, Toshihiro
    Jikuya, Norihiro
    Oi, Masahiro
    Tada, Toshihiko
    Akai, Masaya
    Ishizuka, Tamotsu
    MEDICINE, 2021, 100 (39) : E27385
  • [47] Neoadjuvant Lorlatinib Induces Pathological Complete Response in Advanced ALK-Positive Lung Cancer: A Case Report
    Li, Jie
    Liu, Junwei
    Zhang, Guqin
    Hu, Weidong
    Wang, Xianguo
    Liu, Jun
    AMERICAN JOURNAL OF CASE REPORTS, 2023, 24
  • [48] Transformation from adenocarcinoma to squamous cell lung carcinoma with MET amplification after lorlatinib resistance: A case report
    Ueda, Shoko
    Shukuya, Takehito
    Hayashi, Takuo
    Suzuki, Mario
    Kondo, Akihide
    Arai, Yuta
    Takeshige, Tomohito
    Ninomiya, Hironori
    Takahashi, Kazuhisa
    THORACIC CANCER, 2021, 12 (05) : 715 - 719
  • [49] The efficacy of lorlatinib in a lung adenocarcinoma patient with a novel ALK G1202L mutation: a case report
    Meng, Zhaoting
    Li, Ting
    Wang, Pei
    Lizaso, Analyn
    Huang, Dingzhi
    CANCER BIOLOGY & THERAPY, 2021, 22 (01) : 1 - 4
  • [50] Partial response to lorlatinib in thoracic inflammatory myofibroblastic tumor harboring complex and rare ALK fusions: a case report
    Tang, Li-Bo
    Peng, Ying-Long
    Yang, Xiao-Rong
    Li, Jia-Ting
    Lu, Chang
    Zheng, Mei-Mei
    Sun, Lu
    Yang, Zheng
    Yan, Li-Xu
    Deng, Yu
    Chen, Zhi-Hong
    Lv, Si-Di
    Zhou, Qing
    Xu, Chong-Rui
    TRANSLATIONAL LUNG CANCER RESEARCH, 2025, 14 (02) : 631 - 638
12345